Passage BIO, Inc.
PASGNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PASG. That does not mean none is planned.
Get an email about PASG's next catalysts
Track Passage BIO (PASG) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
PASG Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-2.43 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PBFT02 | Phase 2 | Frontotemporal Dementia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Passage BIO, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Passage BIO, Inc.'s (PASG) pipeline across Phase 2. Its lead program is PBFT02 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Passage BIO, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Passage BIO, Inc. (PASG) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PASG biotech catalysts?→
Add PASG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Passage BIO, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.